We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+71.22%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$729M
AUM Growth
+$327M
Cap. Flow
+$45.1M
Cap. Flow %
6.18%
Top 10 Hldgs %
57.09%
Holding
84
New
23
Increased
22
Reduced
20
Closed
15

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$40.8M
2
UTHR icon
United Therapeutics
UTHR
+$26.2M
3
HSKA
Heska Corp
HSKA
+$20M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$18.2M
5
AZN icon
AstraZeneca
AZN
+$10.8M

Top Sells

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$29.3M
2
ZGNX
Zogenix, Inc.
ZGNX
+$27.8M
3
DHR icon
Danaher
DHR
+$20.4M
4
APLS
Apellis Pharmaceuticals
APLS
+$15.4M
5
GSK icon
GSK
GSK
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 81.4%
2 Miscellaneous 16.98%
3 Communication Services 1.62%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$105M 14.38%
340,000
+280,000
+467% +$82M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$53.1M 7.28%
+954,738
New +$40.8M
TGTX icon
3
TG Therapeutics
TGTX
$8.26B
$48.7M 6.68%
2,501,272
+40,135
+2% +$646K
AMRN
4
Amarin Corp
AMRN
$295M
$33.1M 4.54%
239,305
+64,102
+37% +$8.82M
BHVN
5
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$32.8M 4.49%
448,264
+341,879
+321% +$18.2M
ASND icon
6
Ascendis Pharma A/S
ASND
$16.3B
$32.6M 4.47%
220,344
-55,150
-20% -$7.57M
AZN icon
7
AstraZeneca
AZN
$252B
$29.7M 4.08%
281,076
+104,800
+59% +$10.8M
UTHR icon
8
United Therapeutics
UTHR
$22.1B
$28.2M 3.86%
+232,676
New +$26.2M
ZGNX
9
DELISTED
Zogenix, Inc.
ZGNX
$27.2M 3.73%
1,007,083
-1,006,384
-50% -$27.8M
HSKA
10
DELISTED
Heska Corp
HSKA
$26.1M 3.58%
280,256
+259,485
+1,249% +$20M
DCPH
11
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$25M 3.43%
418,652
+4,571
+1% +$245K
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.51B
$23.1M 3.17%
4,847,792
-2,694,580
-36% -$10.8M
DHR icon
13
Danaher
DHR
$152B
$19.1M 2.62%
121,663
-142,240
-54% -$20.4M
FATE icon
14
Fate Therapeutics
FATE
$291M
$18.2M 2.5%
531,258
+225,773
+74% +$6.73M
ENSG icon
15
The Ensign Group
ENSG
$10.1B
$17.9M 2.46%
427,307
+70,279
+20% +$2.79M
MYOV
16
DELISTED
Myovant Sciences Ltd.
MYOV
$15.7M 2.15%
+760,551
New +$10.3M
APLS
17
DELISTED
Apellis Pharmaceuticals
APLS
$13.7M 1.89%
420,932
-478,542
-53% -$15.4M
MODN
18
DELISTED
MODEL N, INC.
MODN
$11.8M 1.62%
340,764
-33,520
-9% -$977K
SRPT icon
19
Sarepta Therapeutics
SRPT
$2.2B
$11.5M 1.58%
+71,731
New +$9.76M
GSK icon
20
GSK
GSK
$102B
$9.27M 1.27%
181,810
-226,647
-55% -$11.6M
CLDX icon
21
Celldex Therapeutics
CLDX
$3.07B
$9.27M 1.27%
+712,698
New +$3.16M
AUPH icon
22
Aurinia Pharmaceuticals
AUPH
$2.17B
$8.91M 1.22%
+548,325
New +$8.78M
XLV icon
23
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$44.5B
$8.01M 1.1%
+80,000
New +$7.9M
AMRN
24
CALL
Amarin Corp
AMRN
$295M
$7.48M 1.03%
54,015
+2,835
+6% +$390K
LQDA icon
25
Liquidia Corp
LQDA
$6.06B
$7.24M 0.99%
859,724
+615,087
+251% +$4.67M
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2020 Portfolio in Review

As of Q2 2020, Eversept Partners held 84 positions worth $729M, up 81% from $402M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Eversept Partners deployed $45.1M of net new capital in Q2 2020, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 954,738 shares worth $53.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 92% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was ChemoCentryx, Inc., an estimated $29.3M trimmed.

  • Eversept Partners's largest Q2 2020 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 954,738 shares worth $53.1M.
  • Eversept Partners added most to Heska Corp in Q2 2020, an estimated $20M increase.
  • Eversept Partners's biggest Q2 2020 reduction was ChemoCentryx, Inc., cutting an estimated $29.3M.
  • Eversept Partners fully exited Kadmon Holdings, Inc. in Q2 2020, selling an estimated $4.09M.
  • Eversept Partners's ten largest holdings make up 57% of its $729M portfolio in Q2 2020.
  • Eversept Partners opened 23 new positions and closed 15 in Q2 2020.
  • Eversept Partners's portfolio value rose 81% quarter-over-quarter to $729M.

Based on Eversept Partners's 13F filing for Q2 2020, filed 13 Aug 2020.